Literature DB >> 24390270

Mucinous Adenocarcinoma of the Endometrium Compared With Endometrioid Endometrial Cancer: A SEER Analysis.

Jose Alejandro Rauh-Hain1, Roberto J Vargas, Joel Clemmer, Rachel M Clark, Leslie S Bradford, Whitfield B Growdon, Annekathryn Goodman, David M Boruta, John O Schorge, Marcela G del Carmen.   

Abstract

OBJECTIVE: Mucinous endometrial cancer (MEC) is a rare histologic subtype of endometrial cancers. The purpose of this study is to compare the outcomes of patients with MEC with patients with endometrioid endometrial cancers (EEC), and to determine whether there are significant clinicopathologic differences between these tumors.
METHODS: Surveillance, Epidemiology, and End Results (SEER) Program data for 1988 to 2009 was reviewed. Demographic and clinical data were compared. The impact of histology on survival was analyzed using the Kaplan-Meier method. Factors predictive of outcome were compared using the Cox proportional hazards model.
RESULTS: The study group consisted of 104,659 women, 103,097 (98.5%) had EEC and 1562 (1.5%) MEC. The mean age at diagnosis for EEC and MEC was 62 and 63.4, respectively (P<0.001). MEC tumors were more frequently classified as grade 1 (51.3% vs. 44%; P<0.001). In patients with MEC, a higher rate of pelvic lymph node metastasis (16.3% vs. 10.4%; P<0.001) was noted, but not para-aortic lymph node metastasis (5.1% vs. 4%; P=0.1). After adjusting for race, period of diagnosis, SEER registry, marital status, stage, age, surgery, radiotherapy, grade, histology, and lymph node dissection, there was no difference in survival between MEC and EEC (hazard ratio 0.90; 95% confidence interval, 0.78-1.05).
CONCLUSIONS: Mucinous histology does not significantly affect survival when compared with endometrioid histology in endometrial cancer. Patients with MEC were more likely to have positive pelvic lymph nodes at the time of surgery.

Entities:  

Mesh:

Year:  2016        PMID: 24390270     DOI: 10.1097/COC.0000000000000015

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  4 in total

1.  Is mucinous adenocarcinoma of the endometrium a risk factor for lymph node involvement? A multicenter case-control study.

Authors:  Kemal Gungorduk; Aykut Ozdemir; Ibrahim Egemen Ertas; Ilker Selcuk; Ulas Solmaz; Emre Ozgu; Emre Mat; Mehmet Gokcu; Tuba Karadeniz; Serap Akbay; Muzaffer Sanci; Mehmet Mutlu Meydanli; Duygu Ayaz; Tayfun Gungor
Journal:  Int J Clin Oncol       Date:  2014-11-08       Impact factor: 3.402

2.  Frequent promoter methylation of HOXD10 in endometrial carcinoma and its pathological significance.

Authors:  Fan Yang; Dongchen Liu; Yupeng Deng; Jun Wang; Shuyu Mei; Shuang Ge; Hailing Li; Cuijuan Zhang; Tingguo Zhang
Journal:  Oncol Lett       Date:  2020-03-19       Impact factor: 2.967

3.  Role of lymphadenectomy in endometrial cancer with nonbulky lymph node metastasis: Comparison of comprehensive surgical staging and sentinel lymph node algorithm.

Authors:  Francesco Multinu; Jennifer A Ducie; Ane Gerda Zahl Eriksson; Brooke A Schlappe; William A Cliby; Gretchen E Glaser; Tommaso Grassi; Gary L Keeney; Amy L Weaver; Nadeem R Abu-Rustum; Mario M Leitao; Andrea Mariani
Journal:  Gynecol Oncol       Date:  2019-10-08       Impact factor: 5.482

4.  Mucinous adenocarcinoma of the endometrium with metastasis to the clitoral glans after pelvic exenteration for radiation resistant vaginal cuff recurrence.

Authors:  Odinaka Mogor; Emily Hargrave; Demarreta Rush; Kenneth Hatch
Journal:  Gynecol Oncol Rep       Date:  2018-12-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.